Prophylactic Tetracycline Does Not Diminish the Severity of Epidermal Growth Factor Receptor (EGFR) Inhibitor Induced Rash: Results from the North Central Cancer Treatment Group (Supplementary N03CB)1
- Citation:
- Support Care Cancer vol 19 (10) 1601-1607
- Year:
- 2011
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- CCP
- Primary Committee:
- Symptom Inter
- Sec. Committees:
- Health Outcomes
- Pharmas:
- Grants:
- U10 CA035267, U10 CA037417, K24 CA131099, N01 CA035431, U10 CA035269, CA-37404, CA-35090, CA-35195, U10 CA037404, U10 CA063848, U10 CA035195, CA-35103, CA-25224, CA-35113, U10 CA035101, U10 CA035113, CA-63848, U10 CA035415, CA-35415, U10 CA035431, CA-37417, CA-35269, CA-35101, U10 CA025224, U10 CA035090, CA-35267, CA-63849, U10 CA035103
- Corr. Author:
- Authors:
- Aminah Jatoi Shaker R. Dakhil Jeff A. Sloan John W. Kugler Kendrith M. Rowland Paul L. Schaefer Paul J. Novotny Donald B. Wender Howard M. Gross Charles L. Loprinzi
- Networks:
- Study
- NCCTG-N03CB
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- Keywords:
- tetracycline, rash, EGFR inhibitor, EGFR inhibitor-induced rash